

# Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

<https://marketpublishers.com/r/GCB23C7F3C21EN.html>

Date: July 2024

Pages: 88

Price: US\$ 3,480.00 (Single User License)

ID: GCB23C7F3C21EN

## Abstracts

According to our (Global Info Research) latest study, the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market size was valued at USD 5255.3 million in 2023 and is forecast to a readjusted size of USD 6545.8 million by 2030 with a CAGR of 3.2% during review period.

Kidney cancer/ renal cell carcinoma (RCC) is among ten most commonly observed cancer these days. It is sixth common cancer observed in men and it is the tenth most common cause of cancer for women.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs industry chain, the market status of Hospitals (Afinitor (Everolimus), Avastin (Bevacizumab)), Clinic (Afinitor (Everolimus), Avastin (Bevacizumab)), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs.

Regionally, the report analyzes the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.

#### Key Features:

The report presents comprehensive understanding of the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs industry.

The report involves analyzing the market at a macro level:

**Market Sizing and Segmentation:** Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Afinitor (Everolimus), Avastin (Bevacizumab)).

**Industry Analysis:** Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market.

**Regional Analysis:** The report involves examining the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

**Market Projections:** Report covers the gathered data and analysis to make future projections and forecasts for the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs:

**Company Analysis:** Report covers individual Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

**Consumer Analysis:** Report covers data on consumer behaviour, preferences, and attitudes towards Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs. This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals, Clinic).

**Technology Analysis:** Report covers specific technologies relevant to Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs. It assesses the current state, advancements, and potential future developments in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs areas.

**Competitive Landscape:** By analyzing individual companies, suppliers, and consumers, the report presents insights into the competitive landscape of the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

**Market Validation:** The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

## Market Segmentation

Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

## Market segment by Type

Afinitor (Everolimus)

Avastin (Bevacizumab)

Cabomety (Cabozantinib)

Inlyta (Axitinib)

Nexavar (Sorafenib)

Proleukin (Aldesleukin)

Torisel (Temsirrolimus)

Sutent (Sunitinib)

Votrient (Pazopanib)

## Market segment by Application

Hospitals

Clinic

Others

## Market segment by players, this report covers

Active Biotech Ab

Amgen

Bayer AG

Cipla Limited

Roche Holding AG

Glaxosmithkline Plc

Novartis Ag

Pfizer, Inc.

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs, with revenue, gross margin and global market share of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs from 2019 to 2024.

Chapter 3, the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024. and Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market forecast, by regions, type and application, with consumption value, from 2025 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs.

Chapter 13, to describe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs research findings and conclusion.

## Contents

### 1 MARKET OVERVIEW

1.1 Product Overview and Scope of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs by Type

1.3.1 Overview: Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type: 2019 Versus 2023 Versus 2030

1.3.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Type in 2023

1.3.3 Afinitor (Everolimus)

1.3.4 Avastin (Bevacizumab)

1.3.5 Cabomety (Cabozantinib)

1.3.6 Inlyta (Axitinib)

1.3.7 Nexavar (Sorafenib)

1.3.8 Proleukin (Aldesleukin)

1.3.9 Torisel (Temsitrolimus)

1.3.10 Sutent (Sunitinib)

1.3.11 Votrient (Pazopanib)

1.4 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market by Application

1.4.1 Overview: Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application: 2019 Versus 2023 Versus 2030

1.4.2 Hospitals

1.4.3 Clinic

1.4.4 Others

1.5 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size & Forecast

1.6 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast by Region

1.6.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region: 2019 VS 2023 VS 2030

1.6.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region, (2019-2030)

1.6.3 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Prospect (2019-2030)

1.6.4 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and

Prospect (2019-2030)

1.6.5 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Prospect (2019-2030)

1.6.6 South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Prospect (2019-2030)

1.6.7 Middle East and Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Prospect (2019-2030)

## **2 COMPANY PROFILES**

2.1 Active Biotech Ab

2.1.1 Active Biotech Ab Details

2.1.2 Active Biotech Ab Major Business

2.1.3 Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Solutions

2.1.4 Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2019-2024)

2.1.5 Active Biotech Ab Recent Developments and Future Plans

2.2 Amgen

2.2.1 Amgen Details

2.2.2 Amgen Major Business

2.2.3 Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Solutions

2.2.4 Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2019-2024)

2.2.5 Amgen Recent Developments and Future Plans

2.3 Bayer AG

2.3.1 Bayer AG Details

2.3.2 Bayer AG Major Business

2.3.3 Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Solutions

2.3.4 Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2019-2024)

2.3.5 Bayer AG Recent Developments and Future Plans

2.4 Cipla Limited

2.4.1 Cipla Limited Details

2.4.2 Cipla Limited Major Business

2.4.3 Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Solutions



2.4.4 Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2019-2024)

2.4.5 Cipla Limited Recent Developments and Future Plans

2.5 Roche Holding AG

2.5.1 Roche Holding AG Details

2.5.2 Roche Holding AG Major Business

2.5.3 Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Solutions

2.5.4 Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2019-2024)

2.5.5 Roche Holding AG Recent Developments and Future Plans

2.6 Glaxosmithkline Plc

2.6.1 Glaxosmithkline Plc Details

2.6.2 Glaxosmithkline Plc Major Business

2.6.3 Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Solutions

2.6.4 Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2019-2024)

2.6.5 Glaxosmithkline Plc Recent Developments and Future Plans

2.7 Novartis Ag

2.7.1 Novartis Ag Details

2.7.2 Novartis Ag Major Business

2.7.3 Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Solutions

2.7.4 Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2019-2024)

2.7.5 Novartis Ag Recent Developments and Future Plans

2.8 Pfizer, Inc.

2.8.1 Pfizer, Inc. Details

2.8.2 Pfizer, Inc. Major Business

2.8.3 Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Solutions

2.8.4 Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue, Gross Margin and Market Share (2019-2024)

2.8.5 Pfizer, Inc. Recent Developments and Future Plans

### **3 MARKET COMPETITION, BY PLAYERS**

3.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue and Share

*Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market 2024 by Company, Regions, Type and Applicatio...*

by Players (2019-2024)

3.2 Market Share Analysis (2023)

3.2.1 Market Share of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs by Company Revenue

3.2.2 Top 3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players Market Share in 2023

3.2.3 Top 6 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players Market Share in 2023

3.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market: Overall Company Footprint Analysis

3.3.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market: Region Footprint

3.3.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market: Company Product Type Footprint

3.3.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

## **4 MARKET SIZE SEGMENT BY TYPE**

4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value and Market Share by Type (2019-2024)

4.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Forecast by Type (2025-2030)

## **5 MARKET SIZE SEGMENT BY APPLICATION**

5.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Application (2019-2024)

5.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Forecast by Application (2025-2030)

## **6 NORTH AMERICA**

6.1 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type (2019-2030)

6.2 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Application (2019-2030)

6.3 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size

## by Country

6.3.1 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Country (2019-2030)

6.3.2 United States Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

6.3.3 Canada Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

6.3.4 Mexico Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

## 7 EUROPE

7.1 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type (2019-2030)

7.2 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Application (2019-2030)

7.3 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country

7.3.1 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Country (2019-2030)

7.3.2 Germany Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

7.3.3 France Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

7.3.4 United Kingdom Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

7.3.5 Russia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

7.3.6 Italy Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

## 8 ASIA-PACIFIC

8.1 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type (2019-2030)

8.2 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Application (2019-2030)

8.3 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region

8.3.1 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Region (2019-2030)

8.3.2 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

8.3.3 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

8.3.4 South Korea Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

8.3.5 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

8.3.6 Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

8.3.7 Australia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

## **9 SOUTH AMERICA**

9.1 South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type (2019-2030)

9.2 South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Application (2019-2030)

9.3 South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country

9.3.1 South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Country (2019-2030)

9.3.2 Brazil Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

9.3.3 Argentina Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

## **10 MIDDLE EAST & AFRICA**

10.1 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type (2019-2030)

10.2 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Application (2019-2030)

10.3 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country

10.3.1 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs

Consumption Value by Country (2019-2030)

10.3.2 Turkey Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

10.3.3 Saudi Arabia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

10.3.4 UAE Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size and Forecast (2019-2030)

## **11 MARKET DYNAMICS**

11.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Drivers

11.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Restraints

11.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

## **12 INDUSTRY CHAIN ANALYSIS**

12.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Industry Chain

12.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Upstream Analysis

12.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Midstream Analysis

12.4 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Downstream Analysis

## **13 RESEARCH FINDINGS AND CONCLUSION**

## **14 APPENDIX**

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030

Table 2. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030

Table 3. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Region (2019-2024) & (USD Million)

Table 4. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Region (2025-2030) & (USD Million)

Table 5. Active Biotech Ab Company Information, Head Office, and Major Competitors

Table 6. Active Biotech Ab Major Business

Table 7. Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Solutions

Table 8. Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 9. Active Biotech Ab Recent Developments and Future Plans

Table 10. Amgen Company Information, Head Office, and Major Competitors

Table 11. Amgen Major Business

Table 12. Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Solutions

Table 13. Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 14. Amgen Recent Developments and Future Plans

Table 15. Bayer AG Company Information, Head Office, and Major Competitors

Table 16. Bayer AG Major Business

Table 17. Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Solutions

Table 18. Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 19. Bayer AG Recent Developments and Future Plans

Table 20. Cipla Limited Company Information, Head Office, and Major Competitors

Table 21. Cipla Limited Major Business

Table 22. Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Solutions

Table 23. Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)



- Table 24. Cipla Limited Recent Developments and Future Plans
- Table 25. Roche Holding AG Company Information, Head Office, and Major Competitors
- Table 26. Roche Holding AG Major Business
- Table 27. Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Solutions
- Table 28. Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 29. Roche Holding AG Recent Developments and Future Plans
- Table 30. Glaxosmithkline Plc Company Information, Head Office, and Major Competitors
- Table 31. Glaxosmithkline Plc Major Business
- Table 32. Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Solutions
- Table 33. Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 34. Glaxosmithkline Plc Recent Developments and Future Plans
- Table 35. Novartis Ag Company Information, Head Office, and Major Competitors
- Table 36. Novartis Ag Major Business
- Table 37. Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Solutions
- Table 38. Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 39. Novartis Ag Recent Developments and Future Plans
- Table 40. Pfizer, Inc. Company Information, Head Office, and Major Competitors
- Table 41. Pfizer, Inc. Major Business
- Table 42. Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product and Solutions
- Table 43. Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
- Table 44. Pfizer, Inc. Recent Developments and Future Plans
- Table 45. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (USD Million) by Players (2019-2024)
- Table 46. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Share by Players (2019-2024)
- Table 47. Breakdown of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
- Table 48. Market Position of Players in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023

Table 49. Head Office of Key Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players

Table 50. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market: Company Product Type Footprint

Table 51. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market: Company Product Application Footprint

Table 52. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs New Market Entrants and Barriers to Market Entry

Table 53. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Mergers, Acquisition, Agreements, and Collaborations

Table 54. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (USD Million) by Type (2019-2024)

Table 55. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Share by Type (2019-2024)

Table 56. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Forecast by Type (2025-2030)

Table 57. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Application (2019-2024)

Table 58. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Forecast by Application (2025-2030)

Table 59. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type (2019-2024) & (USD Million)

Table 60. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type (2025-2030) & (USD Million)

Table 61. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Application (2019-2024) & (USD Million)

Table 62. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Application (2025-2030) & (USD Million)

Table 63. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Country (2019-2024) & (USD Million)

Table 64. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Country (2025-2030) & (USD Million)

Table 65. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type (2019-2024) & (USD Million)

Table 66. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type (2025-2030) & (USD Million)

Table 67. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Application (2019-2024) & (USD Million)

Table 68. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption



Value by Application (2025-2030) & (USD Million)

Table 69. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Country (2019-2024) & (USD Million)

Table 70. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Country (2025-2030) & (USD Million)

Table 71. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type (2019-2024) & (USD Million)

Table 72. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type (2025-2030) & (USD Million)

Table 73. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Application (2019-2024) & (USD Million)

Table 74. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Application (2025-2030) & (USD Million)

Table 75. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Region (2019-2024) & (USD Million)

Table 76. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Region (2025-2030) & (USD Million)

Table 77. South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type (2019-2024) & (USD Million)

Table 78. South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type (2025-2030) & (USD Million)

Table 79. South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Application (2019-2024) & (USD Million)

Table 80. South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Application (2025-2030) & (USD Million)

Table 81. South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Country (2019-2024) & (USD Million)

Table 82. South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Country (2025-2030) & (USD Million)

Table 83. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type (2019-2024) & (USD Million)

Table 84. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type (2025-2030) & (USD Million)

Table 85. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Application (2019-2024) & (USD Million)

Table 86. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Application (2025-2030) & (USD Million)

Table 87. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Country (2019-2024) & (USD Million)

Table 88. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Country (2025-2030) & (USD Million)

Table 89. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Raw Material

Table 90. Key Suppliers of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Raw Materials

## List Of Figures

### LIST OF FIGURES

- Figure 1. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Picture
- Figure 2. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
- Figure 3. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Type in 2023
- Figure 4. Afinitor (Everolimus)
- Figure 5. Avastin (Bevacizumab)
- Figure 6. Cabomety (Cabozantinib)
- Figure 7. Inlyta (Axitinib)
- Figure 8. Nexavar (Sorafenib)
- Figure 9. Proleukin (Aldesleukin)
- Figure 10. Torisel (Temsirolimus)
- Figure 11. Sutent (Sunitinib)
- Figure 12. Votrient (Pazopanib)
- Figure 13. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
- Figure 14. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Application in 2023
- Figure 15. Hospitals Picture
- Figure 16. Clinic Picture
- Figure 17. Others Picture
- Figure 18. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030
- Figure 19. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value and Forecast (2019-2030) & (USD Million)
- Figure 20. Global Market Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
- Figure 21. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Region (2019-2030)
- Figure 22. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Region in 2023
- Figure 23. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)
- Figure 24. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 25. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 26. South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 27. Middle East and Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 28. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Share by Players in 2023

Figure 29. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023

Figure 30. Global Top 3 Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share in 2023

Figure 31. Global Top 6 Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share in 2023

Figure 32. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Share by Type (2019-2024)

Figure 33. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share Forecast by Type (2025-2030)

Figure 34. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Share by Application (2019-2024)

Figure 35. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share Forecast by Application (2025-2030)

Figure 36. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Type (2019-2030)

Figure 37. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Application (2019-2030)

Figure 38. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Country (2019-2030)

Figure 39. United States Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 40. Canada Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 41. Mexico Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 42. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Type (2019-2030)

Figure 43. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Application (2019-2030)

Figure 44. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs

Consumption Value Market Share by Country (2019-2030)

Figure 45. Germany Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 46. France Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 47. United Kingdom Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 48. Russia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 49. Italy Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 50. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Type (2019-2030)

Figure 51. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Application (2019-2030)

Figure 52. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Region (2019-2030)

Figure 53. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 54. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 55. South Korea Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 56. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 57. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 58. Australia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 59. South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Type (2019-2030)

Figure 60. South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Application (2019-2030)

Figure 61. South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Country (2019-2030)

Figure 62. Brazil Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

Figure 63. Argentina Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)

- Figure 64. Middle East and Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Type (2019-2030)
- Figure 65. Middle East and Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Application (2019-2030)
- Figure 66. Middle East and Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value Market Share by Country (2019-2030)
- Figure 67. Turkey Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)
- Figure 68. Saudi Arabia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)
- Figure 69. UAE Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Consumption Value (2019-2030) & (USD Million)
- Figure 70. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Drivers
- Figure 71. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Restraints
- Figure 72. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Trends
- Figure 73. Porters Five Forces Analysis
- Figure 74. Manufacturing Cost Structure Analysis of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs in 2023
- Figure 75. Manufacturing Process Analysis of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs
- Figure 76. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Industrial Chain
- Figure 77. Methodology
- Figure 78. Research Process and Data Source



## I would like to order

Product name: Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Product link: <https://marketpublishers.com/r/GCB23C7F3C21EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCB23C7F3C21EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

